- Home
- FE vs UTHR Comparison
FE vs UTHR Comparison
Compare FE & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FE
- UTHR
- Stock Information
- Founded
- FE 1996
- UTHR 1996
- Country
- FE United States
- UTHR United States
- Employees
- FE N/A
- UTHR N/A
- Industry
- FE Electric Utilities: Central
- UTHR Biotechnology: Pharmaceutical Preparations
- Sector
- FE Utilities
- UTHR Health Care
- Exchange
- FE Nasdaq
- UTHR Nasdaq
- Market Cap
- FE 23.9B
- UTHR 20.7B
- IPO Year
- FE N/A
- UTHR 1999
- Fundamental
- Price
- FE $46.16
- UTHR $435.34
- Analyst Decision
- FE Buy
- UTHR Buy
- Analyst Count
- FE 15
- UTHR 16
- Target Price
- FE $48.67
- UTHR $472.94
- AVG Volume (30 Days)
- FE 5.0M
- UTHR 629.5K
- Earning Date
- FE 10-22-2025
- UTHR 10-29-2025
- Dividend Yield
- FE 3.87%
- UTHR N/A
- EPS Growth
- FE 48.81
- UTHR 16.08
- EPS
- FE 2.31
- UTHR 26.38
- Revenue
- FE $14,283,000,000.00
- UTHR $3,128,400,000.00
- Revenue This Year
- FE $9.16
- UTHR $13.82
- Revenue Next Year
- FE $3.64
- UTHR $5.71
- P/E Ratio
- FE $19.96
- UTHR $16.63
- Revenue Growth
- FE 7.74
- UTHR 13.50
- 52 Week Low
- FE $37.58
- UTHR $266.98
- 52 Week High
- FE $48.20
- UTHR $479.50
- Technical
- Relative Strength Index (RSI)
- FE 50.97
- UTHR 53.62
- Support Level
- FE $45.15
- UTHR $409.15
- Resistance Level
- FE $46.45
- UTHR $479.50
- Average True Range (ATR)
- FE 0.71
- UTHR 13.51
- MACD
- FE -0.22
- UTHR -0.96
- Stochastic Oscillator
- FE 33.06
- UTHR 37.23
About FE FirstEnergy Corp.
FirstEnergy is an investor-owned holding company with 10 regulated distribution utilities across six mid-Atlantic and Midwestern states. FirstEnergy also owns and operates one of the nation's largest electric transmission systems.
About UTHR United Therapeutics Corporation
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.